Roche’s U.S. biotech subsidiary Genentech has wiped its website of past diversity reports as the company’s diversity and ...
Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...
Kineta has found a new home for deals with Genentech and Merck & Co. Tidying up the portfolio ahead of its merger with TuHURA ...
Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance and Faslodex.
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi ® ...
The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...
About Evrysdi Evrysdi is an SMN2-splicing modifier designed to increase functional SMN protein production. With the introduction of a new tablet formulation, Evrysdi now offers an alternative ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback